Clinical Insights Drive BiVictriX's Approach To Targeted Cancer Therapies
Listed On AIM
Executive Summary
The UK biotech BiVictriX has completed a fundraising and listing on the UK’s AIM to support the development of antibody drug conjugates with “twin-antigen” targeting that could improve the selectivity of cancer therapeutics, with its lead candidate going up against acute myeloid leukemia.
You may also be interested in...
Poolbeg Pharma's Capital-Light Model For New Anti-Infectives Development
A new UK company, Poolbeg Pharma, has been set up to develop new anti-infectives in an efficient manner, and already has a repositioned MAP kinase inhibitor for the treatment of severe influenza ready for Phase II studies.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.